Beth Kendsersky

Placeholder Person Graphic
Retired
Consultant
Beth Kendsersky was a Senior Director in Global Regulatory Affairs, Chemistry, Manufacturing, and Controls at Pfizer; she has retired. Beth led a team and managed global CMC clinical, commercial, and life cycle submissions and approvals for several small molecule drug products. Prior to Pfizer, Beth spent nine years at AstraZeneca Pharmaceuticals and held multiple positions within the regulatory affairs, CMC, and operations brand management teams. She spent 13 years at Sterling Winthrop Research Institute as an analytical chemist focusing on stability, method development, and CMC technical writing. Beth earned her associate degree in medical technology from Dutchess Community College in Poughkeepsie, New York, and her BS in chemistry at the State University of New York at Albany.

Related Articles

An Evaluation of Postapproval CMC Change Timelines
Features
An Evaluation of Postapproval CMC Change Timelines

As the demand for accelerated access to medicines expands globally, the pharmaceutical industry is increasingly submitting regulatory applications in multiple countries simultaneously. As a result, Boards of Health (BoHs) are challenged with approving these applications in an accelerated timeframe and accommodating the submission of postapproval chemistry, manufacturing, and controls (CMC)...

A Proposal for a Comprehensive Quality Overall Summary
Features
A Proposal for a Comprehensive Quality Overall Summary

When working with the common technical dossier (CTD), the structure of Module 2 “follows the scope and outline of the Body of Data in Module 3,”1

  • 1International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. “Concept Paper: M4Q(R2) Common Technical Document on Quality Guideline.” Published 15 November 2021.
Is a Globally Harmonized Quality Overall Summary Possible?
Features
Is a Globally Harmonized Quality Overall Summary Possible?

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline on Registration of Pharmaceuticals for Human Use (M4)1

  • 1International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. “The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality–M4Q (R1)...